Asset Details
Do you wish to reserve the book?
Development of an anti-rat complement C2 antibody that improves renal outcome in a rat kidney transplant model
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Development of an anti-rat complement C2 antibody that improves renal outcome in a rat kidney transplant model
Do you wish to request the book?
Development of an anti-rat complement C2 antibody that improves renal outcome in a rat kidney transplant model
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Development of an anti-rat complement C2 antibody that improves renal outcome in a rat kidney transplant model
2026
Overview
Previously we reported on the therapeutic monoclonal anti-human C2 antibody empasiprubart that inhibits activation of the classical and lectin pathways of complement. Preclinical studies with this antibody are hampered by its low affinity for C2 of animal species other than primates.
We developed a high affinity, Ca
-dependent anti-rat C2 antibody using the sequences and structural data of empasiprubart. Pharmacokinetics and pharmacodynamics of the resulting antibody in Sprague Dawley rats were assessed and used for an intervention study in a rat model of delayed graft function following kidney transplantation. The anti-rat C2 antibody improved kidney function and health in the rats within the first 2 weeks post-transplantation.
Our study shows the successful development of an analogue of empasiprubart that can be used in preclinical
disease models and highlights the potential of C2-blocking as a therapeutic strategy for preventing delayed graft function following kidney transplantation.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
